Please ensure Javascript is enabled for purposes of website accessibility

Here's What Pushed Intellia Therapeutics Inc. Up 33.7% in January

By Cory Renauer - Updated Mar 12, 2018 at 10:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Neither the CRISPR/Cas9 start-up nor its gene-editing peers had much to say last month, but it only took a suggestion of positive signs from elsewhere to send them rocketing higher.

What happened

Shares of Intellia Therapeutics Inc. (NTLA 5.22%), a genome editing start-up, rose 33.7% in January, according to data from S&P Global Market Intelligence. It was a huge month for CRISPR-Cas9 related stocks generally -- for no particular reason -- and Intellia benefited.

So what 

So far, Intellia has shown it can get CRISPR/Cas9 genome-edited hematopoietic stem cells to boost fetal hemoglobin production by 80% to 95% when those cells are transplanted into mice, among other pre-clinical achievements. Unfortunately, the company still can't say when it will be ready to test a candidate derived from its drug-discovery platform in humans.  

Person pointing up towards a multiscreen display.

Image source: Getty Images.

Roughly 1% of novel candidates in pre-clinical development ever make it to an FDA review, and just a fraction of those go on to become blockbuster drugs. Yet despite such long odds, Intellia's market cap is a head-scratching $956 million at the moment.

As is common with hot new biomedical technologies, stocks pegged to the underlying tech tend to make dramatic moves on any related news. So what might have been biggest reason for investors to get excited about Intellia and its peers last month didn't come from the biotechs themselves. Intellia, Editas Medicine (EDIT -0.22%), and Crispr Therapeutics (CRSP 2.78%) all started rising after The Wall Street Journal published a report that suggested Chinese investigators had begun human studies of experimental therapies developed using CRISPR-Cas9 gene-editing techniques years ago.

Now what

So far, Crispr Therapeutics is the first among its peers to give us a timeline for beginning human trials: The tentative front-runner in the niche intends to start them later this year in partnership with Vertex Pharmaceuticals. Intellia sports a couple high-profile partnerships as well. 

Regeneron signed a 10-target deal with Intellia back in 2016 and wants to begin with a transthyretin-related amyloidosis (ATTR) candidate. But neither company has indicated when it expects to file an initial new drug application for their ATTR candidate, which the FDA must approve before they can begin clinical trials.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intellia Therapeutics Stock Quote
Intellia Therapeutics
$53.41 (5.22%) $2.65
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$612.49 (0.84%) $5.10
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
$292.55 (3.19%) $9.05
Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$13.47 (-0.22%) $0.03
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
$66.96 (2.78%) $1.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.